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ABSTRACT 
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide 
synthase and is metabolised by dimethylarginine dimethylaminohydrolase (DDAH). 
Elevated levels of circulating ADMA correlate with various cardiovascular 
pathologies but there is less known on the cellular effects of altered DDAH activity. 
We modified DDAH activity in cells and measured the changes in ADMA levels, 
morphological phenotypes on Matrigel and expression of vascular endothelial growth 
factor (VEGF). DDAH over-expressing ECV304 cells secreted less ADMA and when 
grown in Matrigel, had enhanced tube formation compared to untransfected cells. 
VEGF mRNA levels were 2.1-fold higher in both ECV304 and murine endothelial 
cells (sEnd.1) over-expressing DDAH. In addition the DDAH inhibitor, S-2-amino-
4(3-methylguanidino)butanoic acid (4124W 1mM), markedly reduced human 
umbilical vein endothelial cell (HUVEC) tube formation in vitro. We have found that 
upregulating DDAH activity lowers ADMA levels, increases the levels of VEGF 
mRNA in endothelial cells and enhances tube formation in an in vitro model, whilst 
blockade of DDAH reduces tube formation.  
  
Keywords: Dimethylarginine dimethylaminohydrolase (DDAH), Asymmetric 
dimethylarginine (ADMA), Vascular endothelial growth factor (VEGF), tube 
formation, angiogenesis, endothelial function; nitric oxide (NO); gene expression; 
endogenous nitric oxide synthase inhibitors. 
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INTRODUCTION 
All three isoforms of nitric oxide synthase (NOS) are inhibited by the endogenous 
methylated arginines NGNG-dimethylarginine (ADMA) and L-NG-
monomethylarginine (L-NMMA) [1;2]. These methylarginines are synthesised when 
arginine residues in proteins are methylated by the action of protein arginine 
methyltransferases (PRMT) [3]. As the proteins are hydrolysed, free ADMA and L-
NMMA are released into the cytosol and may compete with L-arginine, the substrate 
for NOSs, and lead to inhibition of nitric oxide (NO) generation. The major route of 
clearance of ADMA and L-NMMA is hydrolysis to citrulline and methylamines by 
dimethylarginine dimethylaminohydrolases (DDAHs) [4;5]. Whilst it is clear that 
increased plasma concentrations of ADMA correlate with various cardiovascular 
pathologies [6-8] and that pharmacological administration of ADMA or L-NMMA 
produces substantial cardiovascular effects [9], there is less known about the effects 
of the endogenous ADMA/DDAH pathway on the behaviour of cells that generate 
ADMA. The aim of the present study was to test the hypothesis that manipulation of 
DDAH activity or expression would alter ADMA levels and affect cell phenotype. 
The focus was on the ability of cells to form “tube-like” structures when grown in 
Matrigel. 
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METHODS  
 
Studies were undertaken in 3 cell types – ECV304 cells, human umbilical vein 
endothelial cells (HUVEC) and the murine endothelial cell line sEnd.1. Studies to 
explore the effects of DDAH over-expression were undertaken using ECV304 cells 
because these cells transfect readily and migrate to form linear “tube-like” structures 
in Matrigel [10;11]. To determine whether the effects seen with ECV304 cells might 
be relevant to endothelial cells we studied human umbilical vein endothelial cells 
(HUVEC) and a murine endothelial cell line sEnd.1. We also used a sEnd.1 cell line 
that over-expresses DDAH-II that we have described previously [12]. 
 
 
Cell culture  
Unless otherwise stated cell culture reagents were purchased from Invitrogen. 
ECV304 cells were grown in M199 medium (Sigma) supplemented with 10 % (v/v) 
foetal bovine serum, penicillin 1000U/ml, streptomycin 1000 µg/ml and L-glutamine 
2 mM as previously described [13]. HUVEC were cultured as described previously 
[4] and used prior to passage 6. sEnd.1 cells were cultured as described previously 
[12]. 
 
Construction of expression plasmids 
Human kidney poly(A)+ RNA was reverse transcribed using an oligo(dT) primer and  
DDAH II cDNA was PCR amplified using primers P1- 
GATCGAATTCAGGATGGGGACGCCGGGG (homologous with nucleotides –2 to 
15, encoding an upstream EcoR1 site, underlined) and P2-
 5 
GATCTCTAGATCAGCTGTGGGGGCGTGTG (homologous with nucleotides 858 
to 840, encoding an upstream Xba1 site, underlined). The PCR product was gel 
purified and cloned into the EcoR1/Xba1 site of the mammalian expression vector 
pcDNA3 (Invitrogen), to give clones D2X7 and D2X10. A reverse orientation DDAH 
II plasmid was constructed by PCR amplification of DDAH II cDNA using primers 
P3-CAGGATCCGATGGGGACGCCGGGGGGGGG (homologous to nucleotides 1 
to 21, encoding an upstream BamH1 site, underlined) and P4- 
CTGAAGCTTCGACCTCTGGCCTACGAGCG (homologous to nucleotides 301 to 
282, encoding a downstream HindIII site, underlined). The gel purified PCR product 
was cloned in the reverse orientation into the HindIII/BamHI site of pcDNA3 
(Invitrogen), to give clones ASD2C and ASD2B. 
 
Transfection of ECV304 cells 
24 h prior to transfection the cells were seeded at 80 % confluence onto a 9 mm petri 
dish. Transfection was carried out using TransFast transfection reagent (Promega) 
according to the manufacturer’s instructions. 48 h after transfection, cells containing 
the expression plasmids were selected by incorporating 800 µg/ml G418 sulphate 
(Sigma) into the cell culture medium. Approximately 10 days after addition of G418 
sulphate, individual colonies of resistant cells were transferred to a 24-well plate 
containing M199 media supplemented with 400 µg/ml G418 sulphate. Cells over-
expressing DDAH II mRNA were screened by northern blotting, using a DDAH II 
cDNA probe.  
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Northern blotting 
Total RNA was extracted from cells using TRIzol reagent (Invitrogen) and probed for 
β-actin and DDAH II as previously described [14]. A human vascular endothelial 
growth factor (VEGF1) cDNA probe was generated by PCR. All mRNA levels 
described were corrected against β-actin mRNA levels. Flk-1 expression was 
determined by binding to 3’ primer (TCTGCAGTGCACCACAAAGACAC), 
designed from human flk-1 sequence (AF035121), and phosphorylated by T4 
polynucleotide kinase (Promega). Transcripts that hybridised to the probes were 
detected using a phosphoimager (Fugi BAS 1000). 
 
Immunoblotting 
Aliquots of cell lysates were resolved by 12% SDS-PAGE, DDAH II was found to 
migrate at 38-40 kDa and was detected using an antibody raised in rabbit against a 
peptide from DDAH II241-255 as previously described [15]. 
 
Cell growth assay 
Cells were seeded onto a 96-well microtiter plate at a density of 500 cells per well and 
grown in ECV304 medium. Cell growth was assayed (in triplicate) over a 4-day 
period using the cell titer 96 Aqueous One solution Cell Proliferation Assay 
(Promega). 
 
Matrigel assay 
ECV304 or HUVEC were overlaid onto 100 µl MatrigelTM (Becton Dickinson) in 24-
well plates. Digital photographs of the cells were collected using an inverted 
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microscope (Axiovert) coupled to an Improvision Apple Macintosh system, each 
experiment was performed in duplicate (n refers to number of duplicates) and 5 
random pictures were taken of each well at a magnification of x 10. The area of linear 
“tube” formation in each picture was analysed, by an individual who was blinded to 
the cell types and treatments, using the Openlab (Improvision) software package and 
all “tubes” across a fixed field of magnification (x 10) were measured [11]. Where 
cells were treated with oxindole or VEGF, data were expressed as  % of control 
(untreated ECV304 cells). 
 
ADMA measurements 
60 % confluent cells were grown in fresh culture medium for 24h. Methylated 
arginines in the conditioned medium were quantitated by HPLC as previously 
described [6].  
 
DDAH activity assay 
Cells were grown to confluence in 150 cm2 flasks, cells were scraped and lysed for 20 
min at 4 °C in sodium phosphate pH 6.6 (10 mM) buffer containing 0.1 % Triton X, 
cleared by centrifugation and assayed for DDAH activity
 
as previously described [4]. 
Statistics 
Results were compared using students unpaired t-test. Values are given as means ± 
SEM where n=3 in separate experiments unless otherwise stated. 
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RESULTS AND DISCUSSION 
Characterization of DDAH II over-expressing ECV304 cells 
To determine whether an increase DDAH activity would alter the behaviour of cells 
that make ADMA we transfected ECV304 cells with the DDAH II over-expression 
construct DDAH II/pCDNA3 to create stable over-expression cell lines. In order to 
achieve results relevant to changes that might occur during physiological 
transcriptional regulation of DDAH [15], we selected lines that over-expressed 
DDAH II by about 2-fold. Basal levels of DDAH II mRNA were 2.3 ± 0.9 (n=5) fold 
higher in D2X10 cells compared to untransfected cells (Fig 1A; p<0.05). 
Immunoblotting of the DDAH II over-expressing ECV304 cells with a polyclonal 
antibody to DDAH II241-255 revealed a distinct band at ~ 40 kDa and confirmed 
increased expression of DDAH II protein (Fig 1B). This increase in protein 
expression was demonstrated to have an effect on DDAH activity since DDAH II 
over-expressing cells converted greater amounts of [14C]L-NMMA to [14C]citrulline 
than untransfected cells (Fig 1C; p<0.05).  
Changes in DDAH activity affected the concentration of ADMA secreted by cells into 
culture media over a 24h period, such that this fell from 6.31 ± 0.21 µg/ml (22.9 ± 0.8 
µM) in control ECV304 cells to 5.10 ± 0.07 µg/ml (18.6 ± 0.3 µM) in the DDAH II 
over-expressing lines (Fig 1D; P<0.01). Levels of SDMA, which is not a DDAH 
substrate, were unchanged between the two cell lines. Consequently, the ratio of 
ADMA: SDMA was 3.23 ± 0.1 and 2.73 ± 0.15 (p=0.024) for ECV304 and the over-
expressing cells respectively (n=5). These results confirm that DDAH activity is a 
determinant of ADMA release by cells and suggest that the intracellular 
concentrations of ADMA/L-NMMA are modulated by this enzyme. The results show 
clearly that increased DDAH activity decreases ADMA accumulation. This is 
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important because the Km of DDAH for ADMA is rather high (150µM) and the 
relevance of DDAH to the control of the low levels of ADMA found in cells and 
tissues has been questioned on theoretical grounds. 
Although altered expression of DDAH clearly affected cell phenotype and behaviour 
(see below) we were unable to determine directly whether this was due to changes in 
NO generation. ECV304 cells are human in origin and produce NO that is at the limit 
of levels of detection. Consequently changes were small, even when cells were 
stimulated with calcium ionophore. It therefore remains possible that the effects of 
DDAH over-expression are independent of NO. This intriguing possibility or the 
possibility of compartmentalised changes in NO should be addressed in future studies. 
  
DDAH II over-expression does not influence cell growth 
The growth of cells was unaffected by DDAH over-expression. When grown under 
standard conditions no differences in cell growth were observed over a 4-day period 
between the untransfected cells and a DDAH over-expressing cell line (Fig 1E). 
DDAH over-expressing cells grown in culture flasks exhibited identical morphology 
to ECV304 cells and the cells transfected with the reverse orientated construct.  
 
DDAH II over-expression enhances tube formation 
Growth of ECV304 cells on Matrigel resulted in cell migration and elongation to form 
“tube-like” structures as described previously [10;16]. Cell lines which over-
expressed DDAH II (Fig 2A) had greater tube formation than either untransfected 
ECV304 cells or cells transfected with a reverse orientated DDAH construct (ASD2B 
& ASD2C) (Fig 2B). This effect is unlikely to be due to an artefact of clonal selection 
since it was reproduced in two independently derived over-expressing lines (D2X7 & 
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D2X10).  The area of the “tubes” after 48 h in DDAH over-expressing cells was  
233.5 ± 48.0 % (D2X7) and 205.1 ± 30.5 (D2X10) compared to control cells (Fig 2B; 
for both cell lines p<0.005, n=4). There was no significant difference in DDAH 
activity or tube formation between the untransfected cells and those transfected with a 
reverse orientated DDAH construct. 
 
Effect of the DDAH inhibitor on tube formation. 
HUVEC also form “tube-like” structures on Matrigel similar to those produced by 
ECV304 cells. Addition of the DDAH inhibitor S-2-amino-4(3-
methylguanidino)butanoic acid, 4124W (1 mM, [4]) reduced tube formation by 
HUVEC from 0.43 ± 0.04 mm2 to 0.25 ± 0.03 mm2 (p<0.001, n=4; Fig 3A & 3B). 
This concentration of 4124W inhibits DDAH isoforms by 96.1 ± 2.1 % and does not 
affect cell viability (Fig 3C;[4]).  
 
VEGF expression is increased in DDAH II over-expressing cells  
VEGF stimulates the formation of tube-like structures by ECV304 and other cell 
types [10;11]. To determine whether VEGF might be involved in the effects of 
DDAH over-expression we assessed expression of VEGF. Northern blotting of 
ECV304 cells with a probe for VEGF showed that in DDAH over-expressing cells 
there was 209 ± 27 % VEGF mRNA compared to wild type cells (p<0.01, n=11; Fig 
4) or cells transfected with the reverse orientated construct. In contrast, mRNA for the 
VEGF receptor flk-1 mRNA was unchanged between DDAH II over-expressing cells 
and untransfected cells (data not shown). Similar results were also observed with 
DDAH II-over-expressing murine endothelial cells (sEnd.1 – data not shown).  
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Effect of a VEGF receptor antagonist on tube formation assays 
DDAH over-expression increases VEGF expression and is associated with the 
enhanced formation of “tube-like” structures. Treatment of ECV304 with VEGF (10 
µg l-1) increased tube formation by 161.2 ± 18.6 %. To determine whether the 
increased tube formation observed by DDAH II over-expression could be reduced by 
interfering with VEGF signalling we used oxindole-1, which competes for the ATP 
binding site on flk-1 [17]. In this series of experiments tube formation in DDAH over-
expressing cells was 193.3 ± 24.0% greater than in untransfected ECV304 cells. 
Addition of oxindole-1 (10 µM) reduced the area of tubes formed by over-expressing 
and wild type cells by 57.7 ± 11.3% and 60.8 ± 7.8 % respectively (Fig 5 A & B). In 
the presence of oxindole-1, tube formation did not differ between ECV304 wild type 
and DDAH over-expressing cells. 
 
SUMMARY 
The results of this study show that DDAH over-expression increases formation of 
tube-like structures and that pharmacological inhibition of DDAH reduces the 
formation of tube-like structures in HUVEC cells. DDAH over-expression is 
associated with an increase in VEGF expression and is blocked by a VEGF Flk-1 
receptor antagonist. These findings clearly show that DDAH is an important 
modulator of the behaviour of cells that make ADMA and that the ADMA/DDAH 
pathway has important paracrine/autocrine functions, probably mediated in part by 
VEGF. It is not known whether the results we have seen are mediated by effects of 
ADMA on NOS pathways (as the cells we have used are of human origin and produce 
very low levels of NO) or whether the effects of ADMA on other arginine handling 
pathways may also be important. The relevance of this in vitro data to in vivo 
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processes such as angiogenesis remains to be determined, however ADMA affects 
angiogenesis in vivo [18], DDAH over-expression in tumour cells leads to the 
formation of more bloody, angiogenic tumours [19] and DDAH II is highly expressed 
in the placenta, a tissue in which angiogenesis is prominent. Furthermore, retinoic 
acid, an angiogenic factor important for embryonic development of the cardiovascular 
system, increases DDAH II expression and NO production [15]. The current study 
strongly suggests that modulation of VEGF and certain basic properties of cell 
phenotype are important actions of the ADMA/DDAH pathway. 
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FIGURE LEGENDS  
Figure 1: Characterisation of DDAHII over-expressing cells 
A] DDAH II mRNA levels are greater in D2X10 than ECV304 cells. 
ECV304 cells transfected with pcDNA3 / DDAH II plasmid (D2X10) contain 2.31 ± 
0.89 fold higher levels of DDAH II mRNA than untransfected cells ECV304 
(*p=0.017, where n=5) as shown by northern blotting where DDAH II mRNA was 
corrected for differences in β-actin mRNA expression. 
B] DDAH II protein is over-expressed in D2X10 cells as determined by 
immunoblotting using a polyclonal rabbit antibody raised against DDAH II241-255. 
Equal amounts of protein were loaded into each lane. 
C] DDAH activity, measured by [14C]L-NMMA conversion to citrulline, is 
significantly enhanced in the DDAH II over-expressing cells D2X10 compared to 
wild type ECV304 cells (*p<0.05, n=3). 
D] Levels of ADMA secreted by 60 % confluent cells into fresh culture media after 
24 h, concentration of ADMA decreased from 22.93 ± 0.75 µM in untransfected 
ECV304 cells to 18.55 ± 0.26 µM in the D2X10 cells (*p<0.01, where n=3). 
E]  DDAH II over-expression does not effect the growth of ECV304 cells.  
Determined by cell proliferation assay (Promega); growth curves of ECV304 and 
D2X10 cells were superimposable. 
 
Figure 2: DDAH activity appears to correspond to Matrigel tube formation  
A] DDAH activity, measured by [14C]L-NMMA conversion to citrulline, is 
significantly enhanced in the DDAH II over-expressing cells D2X7 and D2X10 
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compared to control cells (the wild type ECV304 cells and cells transfected with the 
reverse orientated DDAH construct: ASD2B and ASD2C)  
B] DDAH II over-expression effects the pattern of cells growing on Matrigel. Area of 
tube formation on Matrigel is significantly enhanced in the DDAH II over-expressing 
cells D2X7 (p= 0.004) and D2X10 (p= 0.002) compared to untransfected ECV304 
cells. There was not a significant difference between the wild type ECV304 cells and 
either ASD2B or ASD2C; neither was there a significant difference between the 
D2X7 and D2X10 cell lines, where n=10 from at least 2 independent experiments. All 
analyses of tube area were undertaken by an individual blind to cell type and protocol 
 
Figure 3:  
A] The DDAH inhibitor 4124W (1mM) inhibits Matrigel tube formation. HUVEC 
were plated onto Matrigel and treated ± 4124W (1 mM). Pictures are representative of 
one experiment where n=4 performed in duplicate.  
B] Tube area of HUVEC after 24h fell from 0.43 ± 0.04 mm2 in untreated cells to 
0.25 ± 0.03 mm2 in cells treated with 4124W (*p<0.001, n=4). 
C] DDAH activity of HUVEC lysates, measured by [14C]L-NMMA conversion to 
citrulline, is significantly reduced by 4124W (1mM; **p<0.01, n=3) 
 
Figure 4: DDAH over-expression increases VEGF mRNA levels. 
Northern blotting revealed levels of VEGF mRNA were significantly higher in the 
DDAH II over-expressing cells compared to the untransfected ECV304 cells, where 
n=3, levels of mRNA were corrected against differences in β-actin mRNA expression. 
 
Figure 5: Effect of DDAH II over-expression and oxindole-1 on tube formation 
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A] DDAH II over-expressing and wild type ECV304 cells were plated onto Matrigel, 
the over-expressing cells had significantly higher tube areas than the wild type cells 
(p< 0.05).  Over-expressing and untransfected cells were treated with oxindole-1 (10 
µM) shown after 48 h, this Flk-1 receptor antagonist reduced tube formation. Pictures 
are representative of one experiment where n=4 performed in duplicate. 
B] Effect of Oxindole-1 on tube area. 
ECV304 and D2X10 cells were treated as descried above. Oxindole-1 (10 µM) 
significantly reduces the area of tube formation of DDAH II over-expressing cells by 
60.1 ± 9.7 % ($P= 0.021) and untransfected cells by 36.3 ± 8.1 % (*P< 0.001) 
compared to untreated cells. Values are the total area of tubes formed on Matrigel 
after 48 h, n>4.  
 
 
 





